For inhaled corticosteroids, a high dose generally means more than 500 micrograms per day of fluticasone propionate or its equivalent, though the exact cutoff shifts depending on which drug and inhaler device you use. For oral corticosteroids like prednisone or prednisolone, the picture is different: doses of 37.5 to 50 mg per day during an asthma flare are standard, and what makes oral steroids “high dose” has more to do with how often you take courses and how long each one lasts than with the milligram number on the prescription. The distinction between inhaled and oral matters enormously, because the risks, the benefits, and the logic behind dosing are fundamentally different for each route.
Inhaled Corticosteroid Dose Tiers
Most international asthma guidelines break inhaled corticosteroids (ICS) into three tiers: low, medium, and high. The thresholds are specific to each drug because potency varies. For fluticasone propionate delivered by a metered-dose inhaler, high dose starts at more than 500 micrograms per day in adults. For budesonide, which is less potent per microgram, high dose typically begins above 800 micrograms per day. For beclomethasone dipropionate, the older reference standard, it’s usually above 1,000 micrograms per day. These numbers are rough guides used by the Global Initiative for Asthma (GINA) and similar bodies; individual guidelines sometimes set slightly different boundaries.
One underappreciated wrinkle is that the same drug delivered through a different device can land in a different dose tier. A dry powder inhaler deposits drug in the lungs differently than a pressurized metered-dose inhaler, so 400 micrograms of beclomethasone from one device is not the same effective dose as 400 micrograms from another. Treatment guidelines attempt to account for this with equivalence tables, but the reality is messier. Potency, particle size, lung deposition, and how much drug gets swallowed rather than inhaled all vary, and these differences affect both how well the drug works locally and how much systemic exposure you get. Guidelines that classify ICS formulations purely by dose tend to overlook these pharmacokinetic differences, which can affect the real-world balance between benefit and side effects.1PubMed Central. Inhaled corticosteroids: potency, dose equivalence and therapeutic index
The Dose-Response Curve Is Surprisingly Flat
A natural assumption is that doubling your inhaled steroid dose should roughly double the benefit. The evidence says otherwise. A meta-analysis of budesonide in adult asthma found that roughly 80 to 90 percent of the maximum benefit on lung function and symptoms was already achieved at doses of 200 to 600 micrograms per day. Going from there up to the highest studied dose of 1,600 micrograms per day added only a small extra gain.2European Respiratory Journal. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis A similar pattern holds for fluticasone propionate: comparing 200 micrograms per day with 800 to 1,000 micrograms per day showed statistically significant improvements in airway function at the higher dose, but the actual additional benefit was small.3Respiratory Medicine. What Is Considered a High Dose of Corticosteroids for Asthma?
This shallow dose-response curve is the main reason guidelines push clinicians to try adding a second controller medication before simply cranking up the steroid dose. When researchers compared adding a long-acting bronchodilator to a medium dose of inhaled steroid versus just doubling the steroid dose, the add-on approach reduced asthma attacks more effectively, while doubling the ICS dose alone probably did not reduce flares at all.4Cochrane Database of Systematic Reviews. Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS The upshot: high-dose inhaled steroids are reserved for people whose asthma is genuinely not controlled despite medium doses combined with other therapies, because the extra steroid alone just doesn’t buy much.
That said, when high-dose ICS is used on top of a long-acting bronchodilator, it does appear to help. A systematic review and meta-analysis found that high-dose ICS combined with a long-acting beta-agonist reduced the odds of a severe exacerbation by about 20 percent compared with the same combination at medium dose.5PubMed. The Dose-Response of Inhaled Corticosteroids in Combination Inhaled Corticosteroid/Long Acting Beta(2)-Agonist Maintenance Therapy for Asthma Whether that 20 percent is worth the trade-off in side effects depends on how high your exacerbation risk is to begin with.
Oral Corticosteroid Doses for Asthma Flares
The dosing landscape looks completely different once you cross from inhaled to oral steroids. When someone lands in an emergency department with a severe asthma attack, they typically receive a short course (or “burst”) of oral prednisolone in the range of 30 to 50 mg per day for about five to ten days.6PubMed Central. Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand Meanwhile, older trials comparing low-dose intravenous hydrocortisone (200 mg per day) against high-dose protocols (up to 2,000 mg per day) found no meaningful difference in outcomes, suggesting that higher oral or IV doses do not speed recovery from acute asthma any more than moderate ones.7Australian Prescriber. Corticosteroids – clinical applications: exacerbations of asthma in adults
A Cochrane review looking at different oral steroid regimens for acute asthma reached a consistent conclusion: there was no convincing evidence that a higher dose, a longer course, or a tapered course of prednisolone or dexamethasone produced better outcomes than a lower dose, a shorter course, or an abrupt stop.8The Cochrane Database of Systematic Reviews. Different oral corticosteroid regimens for acute asthma So for acute flares, what makes steroid use “high” isn’t really the per-course dose; it’s the frequency and cumulative exposure over time.
Why Cumulative Oral Steroid Exposure Matters More Than Single-Course Dose
A single five-day burst of prednisone is generally well tolerated. The concern grows with repeat courses. Research has found a clear dose-dependent increase in the risk of adverse events as cumulative lifetime exposure to oral steroids climbs. Harmful effects have been associated with cumulative exposures as low as 0.5 to 1 gram of prednisolone equivalent, which corresponds to roughly four short courses over a lifetime.9European Respiratory Review. Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety For a person taking 40 mg of prednisolone for seven days per course, that threshold is reached surprisingly quickly.
In children, the risks of even short oral steroid bursts deserve separate attention. A large population-based study found that within 5 to 30 days of starting a corticosteroid burst, children had roughly double the risk of pneumonia and sepsis compared with non-use periods.10JAMA Pediatrics. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children The elevations in risk were temporary and mostly faded in the months following the course, but they underscore why clinicians now work hard to minimize how often these bursts are needed.
Side Effects Specific to High-Dose Inhaled Steroids
Inhaled steroids are much safer than oral ones, but “safer” does not mean side-effect-free, especially at high doses. The most common local problems are oral thrush (candidiasis), hoarseness, and a sore throat. A systematic review confirmed that inhaled corticosteroids as a class increase the risk of all three.11PubMed. Review: inhaled corticosteroids increase risk of oral candidiasis, dysphonia, and pharyngitis in persistent asthma The thrush appears to relate in part to local suppression of immune defenses in the mouth. One study found that asthma patients with oral candidiasis had lower levels of a key immune protein in their saliva compared with asthma patients without thrush, suggesting that individual susceptibility plays a role alongside dose.12PubMed. Salivary IgA and oral candidiasis in asthmatic patients treated with inhaled corticosteroid Rinsing your mouth after each dose is a simple step that meaningfully reduces the risk of thrush and hoarseness, and using a spacer with a metered-dose inhaler helps keep more drug in the lungs and less in the back of the throat.
Systemically, high-dose ICS can affect the same organ systems that oral steroids do, just more subtly. The list includes effects on bone density, the adrenal glands, growth in children, the eyes (cataracts, glaucoma), skin thinning, and an increased risk of pneumonia.13PubMed Central. Systemic effects of inhaled corticosteroids: an overview Among these, adrenal suppression is the one that gets the least attention and may cause the most trouble when missed.
Adrenal Suppression at High ICS Doses
Your adrenal glands produce cortisol on their own. When you inhale a corticosteroid daily, some of it reaches the bloodstream and signals the brain to tell the adrenals to dial back. At low and medium ICS doses this effect is typically negligible. At high doses, it can become clinically significant. One case-control study found that current users of high-dose ICS had roughly 1.8 times the odds of adrenal insufficiency compared with non-users.14European Respiratory Journal. The use of inhaled corticosteroids and the risk of adrenal insufficiency A nationwide population-based study put it more starkly, reporting that ICS use independently tripled the risk of developing adrenal insufficiency, with each additional 100 micrograms per day of ICS associated with a 3 percent increase in incidence.15Scientific Reports. Inhaled corticosteroid increased the risk of adrenal insufficiency in patients with chronic airway diseases: a nationwide population-based study
Adrenal insufficiency from ICS can be insidious. Symptoms like fatigue, nausea, dizziness, and poor appetite overlap with many other conditions, so it often goes unrecognized for months. In children, it may also manifest as poor growth velocity. Screening with a morning blood cortisol level is a reasonable first step if your doctor suspects the problem. A very low morning cortisol strongly suggests adrenal insufficiency, while a normal-to-high level makes it unlikely; borderline results can be followed up with a stimulation test.16The Open Respiratory Medicine Journal. Inhaled Corticosteroids and Secondary Adrenal Insufficiency Any child on high-dose inhaled steroids, or anyone with symptoms of adrenal suppression, should be considered for screening.17PubMed Central. Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy
Children and High-Dose Prescribing
Pediatric dose thresholds are lower than adult ones. For children aged 5 to 11, high-dose ICS typically starts above 400 micrograms per day of budesonide equivalent, and for children under 5 the ceiling is even lower. Despite guidelines recommending add-on therapies before escalating ICS dose, observational data suggest that high-dose inhaled steroids are prescribed to about 10 percent of school-age children treated for asthma, with add-on therapy missing in nearly half of those cases.18PubMed Central. High-dose inhaled corticosteroid use in childhood asthma: an observational study of GP prescribing That gap between what guidelines recommend and what actually gets prescribed is one of the bigger safety concerns in pediatric asthma care, because children on high-dose ICS are at particular risk for growth suppression and adrenal insufficiency.
Pregnancy and High-Dose ICS
Pregnancy adds a separate layer of caution. Uncontrolled asthma during pregnancy is clearly harmful to both the mother and the baby, so stopping inhaled steroids out of fear is not the answer. At low and moderate doses, the published evidence supports continuing ICS throughout pregnancy. The picture becomes less clear above 1,000 micrograms per day of beclomethasone equivalent, where data are thinner and some concern exists about potential effects, though whether those doses actually cause adverse outcomes remains uncertain.19PubMed Central. Is it safe to use inhaled corticosteroids in pregnancy? The practical takeaway is to aim for the lowest effective dose that keeps symptoms and flares under control, and to avoid dose escalation without careful review.
Strategies to Avoid or Reduce High-Dose Steroids
Guideline-driven asthma management follows a stepwise approach. The goal at every step is to use the least steroid necessary. Several classes of add-on medication allow you to stay at a lower ICS dose or cut back on oral steroids:
- Long-acting beta-agonists (LABAs): Drugs like salmeterol and formoterol are the most established add-on. Systematic reviews consistently show they allow effective asthma control with lower ICS doses.20PubMed Central. Stepping Down Asthma Treatment: How and When
- Long-acting muscarinic antagonists (LAMAs): Tiotropium and similar drugs have been shown to benefit patients who remain poorly controlled on ICS and LABA combinations, reducing the need for dose escalation or oral steroid courses.21PubMed. Optimizing asthma management: Role of long-acting muscarinic antagonists
- Biologic therapies: For severe asthma, injectable biologics targeting specific immune pathways (like omalizumab, mepolizumab, dupilumab, and others) can dramatically reduce oral steroid dependence. A large pooled analysis of real-world data found that patients who started biologic therapy were roughly two and a half times more likely to stop daily oral steroids entirely compared with similar patients who did not start biologics.22PubMed. Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database
A separate real-world study found that over half of patients who started biologics achieved some reduction in their daily maintenance oral steroid dose within six months, though complete elimination of oral steroids was only slightly more common in the biologic group than in the non-biologic group at that time point.23PubMed Central. Oral Corticosteroid Reduction Between Biologics Initiated and Non-Initiated Patients with Severe Asthma The trajectory improves with longer follow-up, but biologics are not an instant fix. They work best in patients whose asthma is driven by the specific immune pathways the drug targets.
When High Doses Don’t Work: Steroid Resistance
Some patients genuinely do not respond well to corticosteroids at any dose. This phenomenon, sometimes called steroid-resistant or steroid-refractory asthma, affects a minority of people with severe disease. The mechanisms are complex, but at a practical level the issue is that the molecular machinery steroids rely on to reduce inflammation is either suppressed or bypassed. One important factor is reduced activity of a key enzyme involved in gene silencing; when that enzyme’s function is impaired, steroids simply cannot shut down inflammatory genes as effectively.24PubMed Central. Emerging roles and therapeutic implications of HDAC2 and IL-17A in steroid-resistant asthma Other mechanisms include altered steroid receptor function and signaling pathways that interfere with how steroid molecules reach the cell’s DNA.25European Respiratory Review. Cellular mechanisms underlying steroid-resistant asthma
Smoking-related inflammation and a type of airway inflammation driven by neutrophils (rather than the eosinophils more commonly associated with typical asthma) both correlate with poor steroid responsiveness.26PubMed Central. Neutrophilic Inflammation in Asthma and Association with Disease Severity Recognizing steroid-resistant asthma is important because the default clinical instinct when asthma worsens is to increase steroids, but in these patients doing so adds side effects without meaningful benefit. Proper phenotyping and targeted biological therapies are more productive paths forward.
Difficult-to-Treat Versus Truly Severe Asthma
Before concluding that someone’s asthma is genuinely severe enough to warrant high-dose steroids, clinicians are urged to rule out “difficult-to-treat” asthma. The distinction matters: difficult-to-treat asthma looks severe but is actually driven by suboptimal adherence, poor inhaler technique, unaddressed triggers like allergies or acid reflux, or untreated coexisting conditions. Truly severe treatment-refractory asthma persists despite all those factors being optimized.27European Respiratory Journal. Adherence in severe asthma: time to get it right
Studies consistently find that a significant fraction of patients referred to specialist clinics for “severe” asthma turn out to have fixable problems. Using your inhaler incorrectly, for example, can mean that most of the drug never reaches your lungs, making even a high-dose prescription functionally a low dose. Addressing technique, adherence, and comorbidities before escalating therapy is the single most effective way to avoid unnecessary steroid exposure.
Tapering Off High-Dose Therapy
If you have been on high-dose corticosteroids, whether inhaled or oral, stepping down is not as simple as just stopping. For oral steroids used for more than a week or two, the adrenal glands need time to resume their normal production of cortisol. A general principle is that the taper from moderate-to-high doses can proceed relatively briskly at first, but should slow down once you approach the body’s normal physiological level of cortisol production. The longer you have been on suppressive doses, the longer recovery takes, sometimes stretching out over many months.28PubMed Central. The Glucocorticoid Taper: A Primer for the Clinicians
For inhaled steroids, step-down is less fraught but still requires monitoring. Most guidelines suggest cutting the ICS dose by 25 to 50 percent once asthma has been well controlled for at least three months, then watching symptoms and lung function for signs of worsening. Rushing the step-down risks a flare; going too slowly keeps you exposed to side effects you no longer need. The ideal pace is guided by your symptom diary, peak flow readings, and periodic check-ins with your prescriber rather than by a fixed calendar.
How High-Dose ICS Was Studied in Severe Asthma
Much of what we know about the ceiling of inhaled steroid dosing comes from trials that enrolled patients already using fairly high amounts. In one large double-blind trial of 671 patients with severe asthma, all participants were already on between 800 and 2,000 micrograms per day of inhaled steroids before the study began. The trial compared fluticasone propionate at 1,000 micrograms per day against 2,000 micrograms per day, and against budesonide at 1,600 micrograms per day.29European Respiratory Journal. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma Studies like these shaped the modern consensus that 1,000 micrograms per day of fluticasone is essentially the practical ceiling for benefit in most patients, and that going above it seldom changes outcomes.
What these trials collectively tell us is that the concept of “high dose” for inhaled steroids is partly a safety boundary. The dose categories in guidelines are not arbitrary: they are drawn roughly where the benefit curve flattens out and where side-effect risks start to climb more steeply. The high-dose tier exists for the relatively small number of patients whose asthma genuinely requires that level of treatment, and ideally it should be revisited regularly with the goal of stepping back down once control allows.